This technology is a programmable, multiplexed serodiagnostic method that detects SARS-CoV-2 specific epitopes and differentiates these from other human coronavirus epitopes, allowing for precise diagnosis of SARS-CoV-2 exposure.
Sensitive and accurate detection of SARS-CoV-2 exposure is critical for clinical and public health management of COVID-19. Molecular assays are useful in diagnosing active infection, but do not provide insight into historical infections; therefore, antibody testing is needed. However, current serodiagnostic methods are expensive, labor intensive, and do not accurately discriminate among antibodies pertaining to different types of coronaviruses. There remains a need for the development of cost-effective serodiagnostic modalities that specifically and differentially detect SARS-CoV-2 antibodies in patient serum samples.
This technology is a highly multiplexed, microarray-based method for the discovery of coronavirus epitopes. Functional on a variety of platforms, this method identifies peptide sequences that accurately discriminate between antibodies for SARS-CoV-2 and those for related viruses. These peptides may be immobilized to a solid support or conjugated to compounds such as ligands, enzymes, or nanoparticles. As such, this technology has the potential to serve as a SARS-Cov-2 serodiagnostic platform that would have broad applications for medicine and public health.
This technology has allowed for discrimination of antibody responses to epitopes specific to seven distinct coronaviruses. Furthermore, this technology has enabled detection of 29 highly specific IgG epitopes and 16 highly specific IgM epitopes of SARS-CoV-2.
IR CU20309
Licensing Contact: Ron Katz
